Quality of reporting of outcomes in phase III studies of pulmonary tuberculosis: a systematic review

[1] Nunn AJ(2008)Design issues in pivotal drug trials for drug sensitive tuberculosis (TB) Tuberculosis. 88 S85-S92

[2] Phillips PP(2009)Assessment of global capacity to conduct tuberculosis drug development trials: do we have what it takes? Int J Tuberc Lung Dis. 13 1367-1372

[3] Gillespie SH(2012)New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future J Infect Dis. 205 S241-S249

[4] Van Niekerk C(1996)Improving the quality of reporting of randomized controlled trials: The CONSORT statement JAMA. 276 637-639

[5] Ginsberg A(1966)A 5-year study of patients with pulmonary tuberculosis in a concurrent comparison of home and sanatorium treatment for one year with isoniazid plus PAS Bull World Health Organ. 34 533-551

[6] Lienhardt C(1961)Progress in the second and third years of patients with quiescent pulmonary tuberculosis after a year of chemotherapy at home or in sanatorium, and influence of further chemotherapy on the relapse rate Bull World Health Organ. 24 149-175

[7] Raviglione M(2014)High-dose rifapentine with moxifloxacin for pulmonary tuberculosis N Engl J Med. 371 1599-1608

[8] Spigelman M(1982)Tuberculosis treated with rifampicin, ethambutol and isoniazid: Danish tuberculosis trial 1972-1974 Eur J Respir Dis. 63 84-93

[9] Hafner R(2004)Split-drug regimens for the treatment of patients with sputum smear-positive pulmonary tuberculosis--a unique approach Trop Med Int Health. 9 551-558

[10] Jaramillo E(1990)Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in south India Tubercle. 71 253-258

[1] Nunn AJ(2008)Design issues in pivotal drug trials for drug sensitive tuberculosis (TB) Tuberculosis. 88 S85-S92

[2] Phillips PP(2009)Assessment of global capacity to conduct tuberculosis drug development trials: do we have what it takes? Int J Tuberc Lung Dis. 13 1367-1372

[3] Gillespie SH(2012)New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future J Infect Dis. 205 S241-S249

[4] Van Niekerk C(1996)Improving the quality of reporting of randomized controlled trials: The CONSORT statement JAMA. 276 637-639

[5] Ginsberg A(1966)A 5-year study of patients with pulmonary tuberculosis in a concurrent comparison of home and sanatorium treatment for one year with isoniazid plus PAS Bull World Health Organ. 34 533-551

[6] Lienhardt C(1961)Progress in the second and third years of patients with quiescent pulmonary tuberculosis after a year of chemotherapy at home or in sanatorium, and influence of further chemotherapy on the relapse rate Bull World Health Organ. 24 149-175

[7] Raviglione M(2014)High-dose rifapentine with moxifloxacin for pulmonary tuberculosis N Engl J Med. 371 1599-1608

[8] Spigelman M(1982)Tuberculosis treated with rifampicin, ethambutol and isoniazid: Danish tuberculosis trial 1972-1974 Eur J Respir Dis. 63 84-93

[9] Hafner R(2004)Split-drug regimens for the treatment of patients with sputum smear-positive pulmonary tuberculosis--a unique approach Trop Med Int Health. 9 551-558

[10] Jaramillo E(1990)Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in south India Tubercle. 71 253-258